Corie Lok
Corie Lok is Xconomy's Special Projects Editor. Before joining Xconomy in 2017, she was at Nature for 12 years, first as an editor with the Careers section, then as a senior editor who launched Nature Network (a blogging and social networking website), and finally as an editor and features writer on Nature’s news team.
She earned a master’s degree in science journalism from Boston University and was a producer on the science and health beat for two national radio shows at the Canadian Broadcasting Corporation (CBC) in Toronto. She then spent two years covering emerging technologies with MIT Technology Review before arriving at Nature.
Corie is based in Boston and loves reading stories to her young son and playing the obscure but exciting winter sport of curling.
Recent posts
Most drugs target proteins in the cell, but the world of RNA has remained largely untapped by companies making chemical-based, or small-molecule drugs. That’s changing though—just in the last couple of... Read more »
[Updated October 30, 12:15pm ET with further comment, see below.] The immune systems of a large majority of people could already be primed to attack and possibly even disable... Read more »
[Updated 5:41pm ET with analyst note, see below.] When the Trump administration announced its blueprint for lowering prescription drug prices in May, many observers said it was too... Read more »
Centrexion Therapeutics is notable for focusing solely on developing non-opioid, non-addictive pain drugs—an area that biopharma companies have largely avoided. Now the Boston-based startup wants Wall Street’s help with... Read more »
The inventor and developer of a drug, nusinersen (Spinraza), are among the winners of the Breakthrough Prize in Life Sciences. Adrian Krainer (pictured) of Cold Spring Harbor Laboratory and Frank Bennett,... Read more »
The 2nd annual Xconomy Awards Gala was a who’s who of Boston biotech. About 400 people from across the life science ecosystem came out to Boston’s Hynes Convention Center last month... Read more »
A new company has emerged from New York City’s growing startup biotech scene. Gotham Therapeutics launched today with a $54 million Series A round, becoming the second startup since May to... Read more »
[Updated, 11:45 am ET, with comments from press conference] Harnessing the immune system to fight cancer has transformed the treatment of many cancers, and the lives of countless cancer... Read more »
What does the second generation of cancer immunotherapy look like? For Tim Clackson, president of a new biotech launching today, it will hopefully include protein-based drugs that stimulate the immune system... Read more »
Many large drug companies go to extraordinary lengths to fend off generic competition and extend the life of their patents, but Gilead today announced a highly unusual move in the opposite... Read more »
The winners of the U.S.’s most prestigious awards in biomedical sciences were announced today, for work in developing propofol, the world’s most widely used anesthetic drug; for key discoveries in RNA... Read more »
This year’s nominees and finalists for the Xconomy Awards were even more impressive than last year’s (if that’s possible), making it that much tougher for our judges and the editors to... Read more »
When Susan Hockfield (pictured) became president of MIT in 2004, she soon made her mark as the first life scientist to lead the university. She championed the convergence of biology, engineering,... Read more »
With so many stellar Xconomy Award nominees this year, we wanted to recognize several who don’t fit neatly into the other categories, so we’ve created categories just for them. One of... Read more »
Patients are supposed to be at the center of medicine, but the sheer size and complexity of the healthcare and life science industries often makes it challenging to maintain focus on... Read more »
Entrepreneur, scientist, doctor, startup founder, CEO, and in some cases, all of the above. This year’s Young Innovator award finalists—all 35 and under—have shown that they can do it all to... Read more »
[Updated August 3, 9:00am ET, see note below.] With $42 million in new investment, Karuna Pharmaceuticals, a PureTech Health company based in Boston, now has the funds to test... Read more »
Biology research has gotten so precise these days that scientists barely bat an eye when they talk about their ability to study the genome of individual cells or swap out single... Read more »
Shares of Boston-based resTORbio (NASDAQ: TORC) have nearly doubled to roughly $16 apiece, based on positive results the company released this morning from a Phase 2b trial of its drug... Read more »
We at Xconomy are excited to announce that we are honoring Nancy Hopkins, professor emerita at MIT, with our 2018 Lifetime Achievement Award. The award recognizes Hopkins’s career in... Read more »
